Skip to main content

What the FDA labels say about taking them together

Darunavir and maraviroc

Darunavir's FDA label of August 29, 2025 names maraviroc in its drug interactions section; the maraviroc label PlainMeds reads does not name darunavir. The darunavir label: “When used in combination with PREZISTA/ritonavir, the dose of maraviroc should be 150 mg twice daily.”

Check it at the source: the darunavir FDA label on DailyMed (effective August 29, 2025, Janssen Products LP); the maraviroc FDA label on DailyMed (effective September 26, 2022, ViiV Healthcare Company).

What does the darunavir label say about maraviroc?

Darunavir label, drug interactions

Concomitant Drug Class Drug Name Examples: maraviroc; Effect on Concentration of Darunavir Or Concomitant Drug: ↑ maraviroc; Clinical Comment: When used in combination with PREZISTA/ritonavir, the dose of maraviroc should be 150 mg twice daily.

Source: FDA drug label (PREZISTA), Janssen Products LP, effective August 29, 2025 (SPL set 814301f9-c990-46a5-b481-2879a521a16f), via openFDA; the full label on DailyMed

What does the maraviroc label say about darunavir?

Maraviroc's label (effective September 26, 2022) does not name darunavir in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (SELZENTRY), ViiV Healthcare Company, effective September 26, 2022 (SPL set 46f30ac5-c96b-429e-976d-8c5ee1c0761b), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

13Darunavir generic labelers
8Maraviroc generic labelers
DarunavirMaraviroc
Labeled forHIVHIV
Boxed warningNoYes
Pharmacy cost (NADAC)$1.16 per tablet 600 mg tablet$9.15 per tablet 150 mg tablet
Shortage nowNo current entryA presentation being discontinued

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?